These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 19004038

  • 21. Effect of bisphosphonate treatment on bone mineral density in patients with thalassaemia major.
    Skordis N, Ioannou YS, Kyriakou A, Savva SC, Efstathiou E, Savvides I, Christou S.
    Pediatr Endocrinol Rev; 2008 Oct; 6 Suppl 1():144-8. PubMed ID: 19337169
    [Abstract] [Full Text] [Related]

  • 22. Alendronate is effective to treat bone loss in renal transplantation recipients.
    Lan G, Peng L, Xie X, Peng F, Wang Y, Yu S.
    Transplant Proc; 2008 Dec; 40(10):3496-8. PubMed ID: 19100422
    [Abstract] [Full Text] [Related]

  • 23. Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus.
    Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E, Doria AS, Stephens D, Gilday D, Silverman ED.
    Arthritis Rheum; 2007 Jun; 56(6):1966-73. PubMed ID: 17530722
    [Abstract] [Full Text] [Related]

  • 24. Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study.
    Mok CC, To CH, Mak A, Ma KM.
    Arthritis Rheum; 2005 Dec; 52(12):3997-4002. PubMed ID: 16320346
    [Abstract] [Full Text] [Related]

  • 25. The prevention of bone fractures after liver transplantation: experience with alendronate treatment.
    Atamaz F, Hepguler S, Karasu Z, Kilic M, Tokat Y.
    Transplant Proc; 2006 Jun; 38(5):1448-52. PubMed ID: 16797329
    [Abstract] [Full Text] [Related]

  • 26. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation.
    Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D.
    N Engl J Med; 2004 Feb 19; 350(8):767-76. PubMed ID: 14973216
    [Abstract] [Full Text] [Related]

  • 27. [Effect of alendronate on periprosthetic bone loss after cemented primary total hip arthroplasty: a prospective randomized study].
    Nehme A, Maalouf G, Tricoire JL, Giordano G, Chiron P, Puget J.
    Rev Chir Orthop Reparatrice Appar Mot; 2003 Nov 19; 89(7):593-8. PubMed ID: 14699304
    [Abstract] [Full Text] [Related]

  • 28. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study.
    Braith RW, Conner JA, Fulton MN, Lisor CF, Casey DP, Howe KS, Baz MA.
    J Heart Lung Transplant; 2007 Feb 19; 26(2):132-7. PubMed ID: 17258146
    [Abstract] [Full Text] [Related]

  • 29. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
    Sambrook P, Birmingham J, Kelly P, Kempler S, Nguyen T, Pocock N, Eisman J.
    N Engl J Med; 1993 Jun 17; 328(24):1747-52. PubMed ID: 7684512
    [Abstract] [Full Text] [Related]

  • 30. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup.
    Adachi JD, Bensen WG, Bianchi F, Cividino A, Pillersdorf S, Sebaldt RJ, Tugwell P, Gordon M, Steele M, Webber C, Goldsmith CH.
    J Rheumatol; 1996 Jun 17; 23(6):995-1000. PubMed ID: 8782129
    [Abstract] [Full Text] [Related]

  • 31. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J, Cranney A, Goldsmith CH, Bensen WG, Bianchi F, Cividino A, Craig GL, Kaminska E, Sebaldt RJ, Papaioannou A.
    J Rheumatol; 1994 Oct 17; 21(10):1922-6. PubMed ID: 7837160
    [Abstract] [Full Text] [Related]

  • 32. Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.
    Rhew EY, Lee C, Eksarko P, Dyer AR, Tily H, Spies S, Pope RM, Ramsey-Goldman R.
    J Rheumatol; 2008 Feb 17; 35(2):230-6. PubMed ID: 18203323
    [Abstract] [Full Text] [Related]

  • 33. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Marques-Neto JF, Weryha G, Verbruggen N, Hustad CM, Mahlis EM, Melton ME.
    Int J Clin Pract; 2008 Apr 17; 62(4):575-84. PubMed ID: 18324951
    [Abstract] [Full Text] [Related]

  • 34. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: a prospective single-center study.
    Millonig G, Graziadei IW, Eichler D, Pfeiffer KP, Finkenstedt G, Muehllechner P, Koenigsrainer A, Margreiter R, Vogel W.
    Liver Transpl; 2005 Aug 17; 11(8):960-6. PubMed ID: 16035083
    [Abstract] [Full Text] [Related]

  • 35. Decreased bone mineral density in female patients with systemic lupus erythematosus after long-term administration of Tripterygium Wilfordii Hook. F.
    Huang L, Feng S, Wang H.
    Chin Med J (Engl); 2000 Feb 17; 113(2):159-61. PubMed ID: 11775543
    [Abstract] [Full Text] [Related]

  • 36. Factors influencing changes in bone mineral density in patients with anorexia nervosa-related osteoporosis: the effect of hormone replacement therapy.
    Legroux-Gerot I, Vignau J, Collier F, Cortet B.
    Calcif Tissue Int; 2008 Nov 17; 83(5):315-23. PubMed ID: 18836675
    [Abstract] [Full Text] [Related]

  • 37. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S, Takada T, Katsuki Y, Kimura N, Kaneko Y, Suwa A, Hirakata M, Kuwana M.
    J Rheumatol; 2008 Jan 17; 35(1):142-6. PubMed ID: 18050368
    [Abstract] [Full Text] [Related]

  • 38. Alendronate in kidney transplant patients: a single-center experience.
    Toro J, Gentil MA, García R, Pérez-Valdivia MA, García Avellano E, Algarra GR, Pereira P, González-Roncero F, Mateos J.
    Transplant Proc; 2005 Apr 17; 37(3):1471-2. PubMed ID: 15866643
    [Abstract] [Full Text] [Related]

  • 39. Effects of prasterone on bone mineral density in women with systemic lupus erythematosus receiving chronic glucocorticoid therapy.
    Mease PJ, Ginzler EM, Gluck OS, Schiff M, Goldman A, Greenwald M, Cohen S, Egan R, Quarles BJ, Schwartz KE.
    J Rheumatol; 2005 Apr 17; 32(4):616-21. PubMed ID: 15801015
    [Abstract] [Full Text] [Related]

  • 40. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z, Karadag-Saygi E, Unlu-Ozkan F, Akyuz G.
    Aging Male; 2007 Dec 17; 10(4):197-201. PubMed ID: 18033629
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.